Ocugen, Inc. (OCGN)
0.7397
-0.05
(-6.37%)
USD |
NASDAQ |
Oct 23, 16:00
0.7369
0.00 (0.00%)
After-Hours: 20:00
Ocugen Enterprise Value : 238.73M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 238.73M |
| October 22, 2026 | 255.78M |
| October 21, 2026 | 264.29M |
| October 20, 2026 | 263.41M |
| October 19, 2026 | 254.86M |
| October 16, 2026 | 252.49M |
| October 15, 2026 | 263.82M |
| October 14, 2026 | 273.14M |
| October 13, 2026 | 288.13M |
| October 12, 2026 | 309.08M |
| October 09, 2026 | 311.89M |
| October 08, 2026 | 319.32M |
| October 07, 2026 | 326.98M |
| October 06, 2026 | 340.54M |
| October 05, 2026 | 340.54M |
| October 02, 2026 | 333.76M |
| October 01, 2026 | 326.98M |
| September 30, 2026 | 337.15M |
| September 29, 2026 | 357.49M |
| September 28, 2026 | 337.15M |
| September 25, 2026 | 333.76M |
| September 24, 2026 | 326.98M |
| September 23, 2026 | 326.98M |
| September 22, 2026 | 340.54M |
| September 21, 2026 | 337.15M |
| Date | Value |
|---|---|
| September 18, 2026 | 347.32M |
| September 17, 2026 | 337.15M |
| September 16, 2026 | 326.44M |
| September 15, 2026 | 324.78M |
| September 14, 2026 | 347.32M |
| September 11, 2026 | 333.76M |
| September 10, 2026 | 335.46M |
| September 09, 2026 | 349.02M |
| September 08, 2026 | 438.86M |
| September 04, 2026 | 449.04M |
| September 03, 2026 | 445.65M |
| September 02, 2026 | 435.47M |
| September 01, 2026 | 438.86M |
| August 31, 2026 | 438.86M |
| August 28, 2026 | 435.47M |
| August 27, 2026 | 452.43M |
| August 26, 2026 | 465.99M |
| August 25, 2026 | 462.60M |
| August 24, 2026 | 449.04M |
| August 21, 2026 | 459.21M |
| August 20, 2026 | 459.21M |
| August 19, 2026 | 489.72M |
| August 18, 2026 | 442.26M |
| August 17, 2026 | 454.12M |
| August 14, 2026 | 445.65M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.514B |
| Anika Therapeutics, Inc. | 273.50M |
| Gilead Sciences, Inc. | 214.93B |
| MannKind Corp. | 1.314B |
| Nektar Therapeutics | 721.90M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -24.88M |
| Revenue (Quarterly) | 1.488M |
| Total Expenses (Quarterly) | 26.36M |
| EPS Diluted (Quarterly) | -0.0734 |
| Gross Profit Margin (Quarterly) | 60.62% |
| Profit Margin (Quarterly) | -1.67K% |
| Earnings Yield | -34.43% |
| Normalized Earnings Yield | -33.23 |